MedTrace Logo

OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

NCT00097422 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-03-27

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and perform preliminary clinical evaluation in patients with mild to moderate CDAD.

Conditions

Interventions

DRUG

OPT-80

Sponsors & Collaborators

  • Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-01
Primary Completion
2005-04-01
Completion
2005-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00097422 on ClinicalTrials.gov